戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 apillary mucinous neoplasms and 3 pancreatic endocrine tumors).
2  by a gastric carcinoid and not a pancreatic endocrine tumor.
3  which are more than are known for any other endocrine tumor.
4  Thyroid cancer is the most common malignant endocrine tumor.
5  system, accounting for 70% of deaths due to endocrine tumors.
6 , are thus successfully used in PET to image endocrine tumors.
7 se (AADC), the level of which is enhanced in endocrine tumors.
8 sion in both human and mouse MEN1 pancreatic endocrine tumors.
9 which dysregulation of cAMP signaling causes endocrine tumors.
10  7 of 8 (88%) cases of multifocal pancreatic endocrine tumors.
11 , which is mutated in heritable and sporadic endocrine tumors.
12 ce are more susceptible to hematopoietic and endocrine tumors.
13 ntified as a promising marker for pancreatic endocrine tumors.
14 d by multiple endocrine and occasionally non-endocrine tumors.
15 wn of its expression in malignant pancreatic endocrine tumors.
16 astases in patients with sporadic pancreatic endocrine tumors.
17 carcimomas but are never found in pancreatic endocrine tumors.
18                   Pheochromocytomas are rare endocrine tumors.
19 le in the development of sporadic pancreatic endocrine tumors.
20 h diabetes and for targeting menin-sensitive endocrine tumors.
21 advances have been made in the management of endocrine tumors.
22 as, 13 other pancreatic cysts, 27 pancreatic endocrine tumors, 16 chronic pancreatitis, 9 ductal aden
23 c response rate of 25% (45% among pancreatic endocrine tumors, 33% among pheochromocytomas, and 7% am
24 ions were detected in 31 sporadic pancreatic endocrine tumors (34%).
25 sion patterns in normal pancreas, pancreatic endocrine tumors and acinar carcinomas to evaluate their
26  in approximately 40% of sporadic pancreatic endocrine tumors and hypothesize that MENIN is involved
27 cal carcinoma (ACC) is a rare but aggressive endocrine tumor, and the prognostic factors associated w
28  including 12 insulinomas, 28 nonfunctioning endocrine tumors, and four acinar carcinomas.
29 n pancreatic tumors including cystic tumors, endocrine tumors, and intraductal pancreatic mucinous ne
30 a number of nonendocrine tumors and in a few endocrine tumors, and its presence can correlate with tu
31 sias, including myxomas at various sites and endocrine tumors, and lentiginosis.
32 rized by parathyroid hyperplasia, pancreatic endocrine tumors, and pituitary adenomas.
33 ed by spotty skin pigmentation, myxomatosis, endocrine tumors, and schwannomas.
34               In some organs (eg, the lung), endocrine tumors are classified on the basis of mitotic
35                                              Endocrine tumors are often overlooked in medical oncolog
36                                   Pancreatic endocrine tumors are rare but have long held a fascinati
37 l carcinoid tumors and multifocal pancreatic endocrine tumors arise independently or whether they ori
38  Medullary thyroid carcinoma (MTC) is a rare endocrine tumor arising from the C-cells of the thyroid
39 tions in the MEN1 gene on chromosome 11, and endocrine tumors arising in these patients usually show
40 erior pituitary, and pancreatic and duodenal endocrine tumors as well as foregut carcinoids in affect
41                                         Many endocrine tumors can be caused by a variety of different
42 lated adult pancreatic islets and pancreatic endocrine tumor cell lines was determined to compile lis
43 ith (18)F-FDOPA PET/CT imaging in 2 academic endocrine tumor centers was conducted.
44                                              Endocrine tumors (ETs) of pancreas and duodenum occur sp
45              In contrast, RCAS-c-myc induced endocrine tumors exclusively, as determined by histology
46 of chromosome 1 may contribute to pancreatic endocrine tumor formation.
47 es it possible not only to distinguish neuro-endocrine tumors from other forms of pancreatic cancer,
48 erior pituitary, and pancreatic and duodenal endocrine tumors in affected individuals.
49 ome characterized by development of multiple endocrine tumors in affected individuals.
50                                              Endocrine tumors in these patients result when the mutan
51                  Characterization of colonic endocrine tumors in transgenic mice expressing simian vi
52                          In gastrointestinal endocrine tumors including gastrinomas, little data are
53 ur understanding of the hereditary nature of endocrine tumors increases, the role of genetic counseli
54 nsus region they may play a role in sporadic endocrine tumors independent of the MEN1 gene or in othe
55     The molecular pathogenesis of pancreatic endocrine tumors is largely unknown.
56  unregulated secretion often associated with endocrine tumors may result, at least in part, from inef
57 cinoma, n = 17; sarcoma/melanoma, n = 4; and endocrine tumor, n = 6).
58 ved sunitinib (carcinoid, n = 41; pancreatic endocrine tumor, n = 66).
59                                   Pancreatic endocrine tumors occur both sporadically and as part of
60                                              Endocrine tumors of the gastrointestinal tract produce a
61  LOH rates of parathyroid lesions (100%) and endocrine tumors of the pancreas (83%) were strikingly d
62 iology, diagnosis, imaging, and treatment of endocrine tumors of the pancreas.
63 3p was identified in 33% of 43 patients with endocrine tumors of the pancreas.
64 astrointestinal submucosa and the islet cell endocrine tumors of the pancreas.
65  alterations that override these controls in endocrine tumors often are not associated with oncogenes
66  Forty-two patients with advanced pancreatic endocrine tumors or carcinoid tumors were treated with r
67  objective response rate (ORR) in pancreatic endocrine tumor patients was 16.7% (11 of 66 patients),
68              Carcinoid tumors and pancreatic endocrine tumors (PETs) are uncommon neuroendocrine neop
69                                   Pancreatic endocrine tumors (PETs) have long fascinated clinicians
70 nomas as well as other functional pancreatic endocrine tumors (PETs) in whom the excess-hormone state
71 he pathogenesis of sporadic human pancreatic endocrine tumors (PETs).
72                             In human adrenal endocrine tumors (pheochromocytoma), gallein attenuated
73 ine neoplasia type 1 (MEN1) develop multiple endocrine tumors, primarily affecting the parathyroid, p
74                                              Endocrine tumors such as aldosterone-producing adrenal a
75 l molecule Gbetagamma inhibition in treating endocrine tumors such as pheochromocytoma, in addition t
76                                              Endocrine tumors, such as parathyroid adenomas and pheoc
77 sent in both benign and malignant pancreatic endocrine tumors, suggesting that a MENIN gene mutation
78 in, a protein previously characterized as an endocrine tumor suppressor and transcriptional regulator
79 hromosome 3p25 may harbor a novel pancreatic endocrine tumor suppressor gene, and allelic loss of thi
80 NETs occur either sporadically or as part of endocrine tumor susceptibility syndromes such as multipl
81 s regimen appeared more active in pancreatic endocrine tumors than in carcinoid tumors.
82       Gastrinomas are rare gastrin-secreting endocrine tumors that usually arise in the duodenum or p
83                                   As in many endocrine tumors, there are no uniform definitive histol
84               Thirty-one sporadic pancreatic endocrine tumors were analyzed for mutation of MENIN by
85                                   Pancreatic endocrine tumors were found in all patients at surgery,
86     Twenty-nine sporadic and MEN1 pancreatic endocrine tumors were studied for loss of heterozygosity
87 inoid tumors and eight multifocal pancreatic endocrine tumors, were studied.
88 ine tumors include carcinoids and pancreatic endocrine tumors, which share a number of common feature
89     Adrenocortical Carcinoma (ACC) is a rare endocrine tumor with poor overall prognosis and 1.5-fold
90                     Patients with pancreatic endocrine tumors with liver metastases should undergo SR
91 activation of the Men1 in pancreas developed endocrine tumors with no exocrine tumor manifestation, r
92 ntinued inclusion and analysis of pancreatic endocrine tumors with small intestinal neuroendocrine tu